2338 Efficacy and safety of sorafenib as first-line therapy of patients (pts) with advanced Child-Pugh B Hepatocellular Carcinoma (HCC): A systematic review and meta-analysis

2015 ◽  
Vol 51 ◽  
pp. S446
Author(s):  
M. McNamara ◽  
A. Slagter ◽  
C. Rigby ◽  
A. Lamarca ◽  
J. Valle ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis

2006 ◽  
Vol 24 (11) ◽  
pp. 2131-2141 ◽  
Author(s):  
Hazel A Bradley ◽  
Charles Shey Wiysonge ◽  
Jimmy A Volmink ◽  
Bongani M Mayosi ◽  
Lionel H Opie
Keyword(s):  
Systematic Review ◽  
Beta Blockers ◽  
Meta Analysis ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 616
Author(s):  
Mohamed A. Abd El Aziz ◽  
Antonio Facciorusso ◽  
Tarek Nayfeh ◽  
Samer Saadi ◽  
Mohamed Elnaggar ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Survival Outcomes ◽  
Efficacy And Safety ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited therapeutic options. One of these options is immune checkpoint inhibitors. The aim of this study is to comprehensively review the efficacy and safety of immune checkpoint inhibitors for patients with HCC.

Sign in / Sign up

Export Citation Format

Share Document